EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis

Wen Du, Zijin Chen, Zhengyin Fang, Junru Li, Qinjie Weng, Qimin Zheng, Lin Xie, Hanlan Yu, Xiangchen Gu, Hao Shi, Zhaohui Wang, Hong Ren und 3 weitere

Clinical Kidney Journal · 30.11.2023 · 16 (12) · 2567-2577

DOI: 10.1093/ckj/sfad164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 13.07.2023. Verfasst von Wen Du und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute of Nephrology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Major International Joint Research Programme, National Natural Science Foundation of China, Shanghai Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few studies have evaluated the treatment of immunoglobulin A nephropathy (IgAN) patients with nephrotic syndrome (NS) and mesangioproliferative glomerulonephritis (MPGN). The aim of this study was to compare the therapeutic effects of oral glucocorticoids (GCS) combined with intravenous cyclophosphamide (CTX) and oral GCS alone in the treatment of the MPGN-IgAN patients with NS.

Methods

Biopsy-proven primary IgAN patients who were aged ≥14 years at diagnosis, had coexistent NS and MPGN and estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m2, and were treated by oral GCS combined with intravenous CTX or oral GCS alone for 6–12 months were retrospectively included. The patients in the GCS + CTX (prednisone 0.6–0.8 mg/kg/day and intravenous CTX 0.6–1.0 g monthly) or GCS (prednisone 0.8–1 mg/kg/day) group were rather matched at a 1:1 ratio on key characteristics by propensity score matching. The primary outcome was defined as either complete remission or partial remission at Month 24. The secondary outcome was a composite renal endpoint defined as a 50% decline in eGFR, doubling of serum creatinine or progression to end-stage kidney disease.

Results

Among the 146 IgAN patients who met the inclusion criteria, 42 patients were enrolled in the GCS + CTX group, and 42 patients were enrolled in the GCS group after propensity score matching. The clinical and histological parameters were similar between the two groups. Remission occurred more frequently in the GCS + CTX group at Month 6 (88.1% vs 52.4%, P < 0.001), Month 12 (88.1% vs 56.1%, P = 0.001) and Month 24 (85.0% vs 47.5%, P < 0.001) than in the GCS group. Moreover, subgroup analysis revealed that the higher response rate at Month 24 in the GCS + CTX group than in the GCS group was also present in different subgroups defined by sex, age, eGFR or Oxford MEST-C. Notably, we found that eGFR decreased at a lower rate in patients from the GCS + CTX group than in patients from the GCS group [eGFR slope: 0.05(–3.09, 3.67) vs –2.56 (–11.30, 0.86) mL/min/1.73 m2/year, P = 0.03]. Based on multivariate Cox regression analysis, GCS + CTX treatment was found to be independently associated with a decrease in risk for the composite endpoint after adjusted by the International Risk Prediction Score with race (hazard ratio = 0.17, 95% confidence interval 0.04–0.83, P = .03). There was no significant difference in adverse events (50.0% vs 42.9%, P = 0.51) or serious adverse events (7.1% vs 11.9%, P = .71) between the two groups.

Conclusions

Oral GCS combined with intravenous CTX is superior to GCS alone in treating MPGN-IgAN patients combined with NS. As the retrospective design and small sample size, our findings need to be validated by a prospective study.

Schlagwörter

Stichwörter der Autor:innen

IgA nephropathycyclophosphamideglucocorticoidsnephrotic syndromeprognosis

Autor:innen und Institutionen

  • Department of Nephrology, Institute of Nephrology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.

Förderung

  • Major International Joint Research Programme
  • National Natural Science Foundation of China
  • Shanghai Science and Technology Commission
  • Science and Technology Innovation Action Plan of Shanghai Science and Technology Committee
  • Shanghai Municipal Education Commission
  • Gaofeng Clinical Medicine
  • Shanghai Shenkang Hospital Development Center
  • Shanghai Jiao Tong University School of Medicine

Zitieren

APA

Du, W., Chen, Z., Fang, Z., Li, J., Weng, Q., Zheng, Q., Xie, L., Yu, H., Gu, X., Shi, H., Wang, Z., Ren, H., Wang, W., Ouyang, Y., & Xie, J. (2023). Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis. Clinical Kidney Journal, 16(12), 2567-2577. https://doi.org/10.1093/ckj/sfad164

Vancouver

Du W, Chen Z, Fang Z, Li J, Weng Q, Zheng Q, et al. Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis. Clinical Kidney Journal. 2023;16(12):2567-2577. doi:10.1093/ckj/sfad164

BibTeX
@article{Du2023,
  author = {Du, Wen and Chen, Zijin and Fang, Zhengyin and Li, Junru and Weng, Qinjie and Zheng, Qimin and Xie, Lin and Yu, Hanlan and Gu, Xiangchen and Shi, Hao and Wang, Zhaohui and Ren, Hong and Wang, Weiming and Ouyang, Yan and Xie, Jingyuan},
  title = {Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis},
  journal = {Clinical Kidney Journal},
  year = {2023},
  volume = {16},
  number = {12},
  pages = {2567--2577},
  doi = {10.1093/ckj/sfad164}
}
Kostenlos starten →